Ï㽶ÊÓƵ

Eric L. Snyder

Eric L. Snyder, MD, PhD

Languages spoken: English

  • Specialties

    • Pathology, Anatomical

    Board Certification

    American Board of Pathology (Sub: Anatomic Path)

  • Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Oncological Sciences -Adjunct
    Board Certification
    American Board of Pathology (Sub: Anatomic Path)

    Education history

    Research Fellow Massachusetts Institute of Technology Postdoctoral Research Fellow
    Anatomic Pathology - Brigham and Women's Hospital Resident
    Other Training Ï㽶ÊÓƵ of California, San Diego Visiting Scholar
    Molecular/Cellular Biology - Washington Ï㽶ÊÓƵ School of Medicine in St. Louis M.D., Ph.D.
    Undergraduate Biology with Honors - Pennsylvania State Ï㽶ÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Orstad G, Fort G, Parnell TJ, Jones A, Stubben C, Lohman B, Gillis KL, Orellana W, Tariq R, Klingbeil O, Kaestner K, Vakoc CR, Spike BT, Snyder EL (2022). FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma. Dev Cell, 57(15), 1866-1882.e10. ()
    2. Ingram K, Samson SC, Zewdu R, Zitnay RG, Snyder EL, Mendoza MC (2021). NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity. Oncogene, 41(2), 293-300. ()
    3. Camolotto SA, Belova VK, Torre-Healy L, Vahrenkamp JM, Berrett KC, Conway H, Shea J, Stubben C, Moffitt R, Gertz J, Snyder EL (2020). Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Gut, 70(5), 900-914. ()
    4. Kinsey CG, Camolotto SA, Boespflug AM, Gullien KP, Foth M, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavlieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL and McMahon M (2019). Protective autophagy elicited by RAF-> MEK -> ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627.
    5. Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL (2018). FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife, 7. ()
    6. Caswell DR, Chuang CH, Ma RK, Winters IP, Snyder EL, Winslow MM (2018). Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma. Mol Cancer Res, 16(11), 1737-1749. ()
    7. Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, Bhutkar A, Vahrenkamp JM, Berrett KC, Cessna MH, Lane TE, Witt BL, Salama ME, Gertz J, Jones KB, Snyder EL, Oliver TG (2018). The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity, 49(4), 764-779.e9. ()
    8. Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, Gertler FB, Jacks T (2015). Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev, 29(17), 1850-62.
    9. Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL (2014). c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol, 234(2), 190-202. ()
    10. Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner AJ (2014). Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther, 13(9), 2184-93. ()
    11. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E (2013). Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev, 27(13), 1447-61. ()
    12. Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T (2013). Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell, 50(2), 185-99. ()
    13. Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson M (2013). Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev, 27(2), 197-210. ()
    14. Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD, Look AT (2011). Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A, 108(39), 16386-91. ()
    15. Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T (2011). Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev, 25(14), 1470-5. ()
    16. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T (2011). Suppression of lung adenocarcinoma progression by Nkx2-1. Nature, 473(7345), 101-4. ()
    17. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M (2010). Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A, 107(18), 8352-6. ()
    18. Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T (2009). Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell, 16(5), 379-89. ()
    19. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M (2009). Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest, 89(8), 857-66. ()
    20. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD (2009). c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol, 218(3), 292-300. ()
    21. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak K (2008). Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A, 105(37), 14076-81. ()
    22. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, Dowdy SF (2005). Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res, 65(23), 10646-50. ()
    23. Snyder EL, Meade BR, Saenz CC, Dowdy SF (2004). Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol, 2(2), E36. ()
    24. Yu BD, Becker-Hapak M, Snyder EL, Vooijs M, Denicourt C, Dowdy SF (2003). Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proc Natl Acad Sci U S A, 100(25), 14881-6. ()
    25. Snyder EL, Meade BR, Dowdy SF (2003). Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. J Control Release, 91(1-2), 45-51. ()
    26. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK (2001). hADA3 is required for p53 activity. EMBO J, 20(22), 6404-13. ()
    27. Bollag B, Prins C, Snyder EL, Frisque RJ (2000). Purified JC virus T and T' proteins differentially interact with the retinoblastoma family of tumor suppressor proteins. Virology, 274(1), 165-78. ()
    28. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF (1998). Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med, 4(12), 1449-52. ()
    29. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K, Croce CM (1997). Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A, 94(26), 14584-9. ()
    30. Rzhetsky A, Dopazo J, Snyder E, Dangler CA, Ayala FJ (1996). Assessing dissimilarity of genes by comparing their RNAse A mismatch cleavage patterns. Genetics, 144(4), 1975-83. ()

    Review

    1. Camolotto SA, Belova VK, Snyder EL (2019). The role of lineage specifiers in pancreatic ductal adenocarcinoma. [Review]. J Gastrointest Oncol, 9(6), 1005-1013.
    2. Farago AF, Snyder EL, Jacks T (2012). SnapShot: Lung cancer models. [Review]. Cell, 149(1), 246-246.
    3. Snyder EL, Dowdy SF (2005). Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. [Review]. Expert Opin Drug Deliv, 2(1), 43-51. ()
    4. Snyder EL, Dowdy SF (2004). Cell penetrating peptides in drug delivery. [Review]. Pharm Res, 21(A), 389-393.
    5. Snyder EL, Dowdy SF (2001). Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. [Review]. Curr Opin Mol Ther, 3(2), 147-52. ()

    Editorial

    1. Gumbleton M, Snyder EL (2023). TTF-1 and immune checkpoint therapy in non-small cell lung cancer. Transl Lung Cancer Res, 12(3), 398-400. ()